➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Baxter
Medtronic
McKinsey
AstraZeneca

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,546,428

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,546,428 protect, and when does it expire?

Patent 8,546,428 protects SIRTURO and is included in one NDA.

This patent has thirty-nine patent family members in thirty-three countries.

Summary for Patent: 8,546,428
Title:Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-- beta-phenyl-3-quinolineethanol
Abstract: The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-- beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.
Inventor(s): Hegyi; Jean Francois Alexandre Lucas (Diest, BE), Aelterman; Wim Albert Alex (Gierle, BE), Lang; Yolande Lydia (Vosselaar, BE), Stokbroekx; Sigrid Carl Maria (Beerse, BE), Leys; Carina (Stabroek, BE), Van Remoortere; Peter Jozef Maria (Kapellen, BE), Faure; Anne (Vosselaar, BE)
Assignee: Janssen Pharmaceutica NV (Beerse, BE)
Application Number:12/515,986
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Formulation; Use;

Recent additions to Drugs Protected by US Patent 8,546,428

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Janssen Therap SIRTURO bedaquiline fumarate TABLET 204384 May 27, 2020 RX Yes   Start Trial Y Y   Start Trial U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
Janssen Therap SIRTURO bedaquiline fumarate TABLET 204384 Dec 28, 2012 RX Yes   Start Trial Y Y   Start Trial U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,546,428

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-001 Dec 28, 2012 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,546,428

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06125443Dec 5, 2006
PCT Information
PCT FiledDecember 03, 2007PCT Application Number:PCT/EP2007/063186
PCT Publication Date:June 12, 2008PCT Publication Number: WO2008/068231

International Family Members for US Patent 8,546,428

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2498   Start Trial
Argentina 064149   Start Trial
Australia 2007328945   Start Trial
Brazil PI0719693   Start Trial
Canada 2668512   Start Trial
Chile 2007003472   Start Trial
China 101547904   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
Express Scripts
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.